Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H26O2 |
Molecular Weight | 274.3985 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]12CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]3([H])[C@]2([H])CC[C@]1([H])O
InChI
InChIKey=NPAGDVCDWIYMMC-IZPLOLCNSA-N
InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1
DescriptionSources: https://www.drugs.com/pro/nandrolone.htmlCurator's Comment:: Description was created based on several sources, including
https://empower.pharmacy/drugs/nandrolone-decanoate-injection.html
https://us.basicstero.info/nandrolones
Sources: https://www.drugs.com/pro/nandrolone.html
Curator's Comment:: Description was created based on several sources, including
https://empower.pharmacy/drugs/nandrolone-decanoate-injection.html
https://us.basicstero.info/nandrolones
Nandrolone, also known as 19-nortestosterone or 19-norandrostenolone, is a semisynthetic anabolic-androgenic steroid derived from testosterone. Nandrolone is used in the form of a variety of long-acting prodrug esters for intramuscular injection, the most common of which are nandrolone decanoate. Nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are therefore similar to those of male sex hormones with the possibility of causing serious disturbances of growth and sexual development if given to young children. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testis. Anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. Synthetic version of nandrolone was developed in 1950. But nandrolone for sale appeared later only in 1962 in the form of decanoate under the trade name Deca-Durabolin (Organon company).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18809391 |
|||
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NANDROLONE DECANOATE Approved UseNandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Surgically induced anephric patients have been reported to be less responsive. Launch Date1.28312646E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
36.1 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10435281 |
6 mL single, oral dose: 6 mL route of administration: Oral experiment type: SINGLE co-administered: |
NANDROLONE PHENPROPIONATE blood | Sus scrofa population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
219.9 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10435281 |
6 mL single, oral dose: 6 mL route of administration: Oral experiment type: SINGLE co-administered: |
NANDROLONE PHENPROPIONATE blood | Sus scrofa population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
A report on alterations to the speaking and singing voices of four women following hormonal therapy with virilizing agents. | 1999 Dec |
|
Detection of nandrolone, testosterone, and their esters in rat and human hair samples. | 1999 Oct |
|
Sport nutritional supplements: quality and doping controls. | 2001 |
|
The effect of anabolic steroid on the distribution of muscle fiber in rat hind limb. | 2001 |
|
[The combined effect of retabolile and support loads on the post-traumatic reparation process in suspended rat muscles]. | 2001 |
|
Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. | 2001 |
|
[What is the role of hormonal treatments in acne?]. | 2001 Apr |
|
Steroidal control of male hamster sexual behavior in Me and MPOA: effects of androgen dose and tamoxifen. | 2001 Apr |
|
Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. | 2001 Apr |
|
The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. | 2001 Apr |
|
15N NMR relaxation studies of backbone dynamics in free and steroid-bound Delta 5-3-ketosteroid isomerase from Pseudomonas testosteroni. | 2001 Apr 3 |
|
Effects of nandrolone treatment on recovery in horses after strenuous physical exercise. | 2001 Aug |
|
Measurement of androgen and estrogen receptors in breast tissue from subjects with anabolic steroid-dependent gynecomastia. | 2001 Aug 17 |
|
The effects of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism. | 2001 Dec |
|
Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. | 2001 Dec |
|
Expression of the human androgen receptor in eukaryotic cells using a recombinant adenovirus vector yields high levels of the soluble, functional receptor protein. | 2001 Dec |
|
Anabolic steroid abuse and cardiac sudden death: a pathologic study. | 2001 Feb |
|
Urinary nandrolone metabolites of endogenous origin in man: a confirmation by output regulation under human chorionic gonadotropin stimulation. | 2001 Jan |
|
The anabolic-androgenic steroid nandrolone decanoate affects the density of dopamine receptors in the male rat brain. | 2001 Jan |
|
Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. | 2001 Jan-Feb |
|
Novel amino acid substitutional mutation, tyrosine-739-aspartic acid, in the androgen receptor gene in complete androgen insensitivity syndrome. | 2001 Jun |
|
Differential effects of nandrolone decanoate in fast and slow rat skeletal muscles. | 2001 Mar |
|
[Treatment of endometriosis with dienogest: preliminary report]. | 2001 May |
|
Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods. | 2001 May |
|
Aggression in male rats receiving anabolic androgenic steroids: effects of social and environmental provocation. | 2001 Nov |
|
Effect of nandrolone decanoate on the lipid profile of male peritoneal dialysis patients. | 2001 Nov-Dec |
|
Endogenous origin of norandrosterone in female urine: indirect evidence for the production of 19-norsteroids as by-products in the conversion from androgen to estrogen. | 2001 Oct |
|
Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. | 2001 Oct 1 |
|
[Urinary nandrolone metabolites in antidoping control]. | 2001 Sep |
|
Estimation of hormone replacement therapy influence on serum galanin level in postmenopausal women. | 2001 Sep |
|
Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. | 2001 Sep |
|
Determination of nandrolone and metabolites in urine samples from sedentary persons and sportsmen. | 2001 Sep 25 |
|
Effect of combined treatment with nandrolone and cocaine on the NMDA receptor gene expression in the rat nucleus accumbens and periaqueductal gray. | 2002 |
|
Role of androgens in female genital sexual arousal: receptor expression, structure, and function. | 2002 Apr |
|
Randomized prospective comparison between erythropoietin and androgens in CAPD patients. | 2002 Apr |
|
Aromatase and breast cancer: W39R, an inactive protein. | 2002 Apr |
|
Effects of withdrawal from anabolic androgenic steroids on aggression in adult male rats. | 2002 Apr 1 |
|
Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. | 2002 Aug |
|
Metabolic effects of nandrolone decanoate and resistance training in men with HIV. | 2002 Dec |
|
Abuse of performance-enhancing drugs in sport. | 2002 Feb |
|
Role of IGF-I and IGF-binding proteins within diaphragm muscle in modulating the effects of nandrolone. | 2002 Feb |
|
Hair analysis of seven bodybuilders for anabolic steroids, ephedrine, and clenbuterol. | 2002 Jan |
|
Human nutritional supplements in the horse: comparative effects of 19-norandrostenedione and 19-norandrostenediol on the 19-norsteroid profile and consequences for doping control. | 2002 Jan 25 |
|
The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. | 2002 Jul |
|
Steroid receptor concentration in aged rat hindlimb muscle: effect of anabolic steroid administration. | 2002 Jul |
|
Treatment for HIV wasting withdrawn. | 2002 Jun |
|
Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels. | 2002 Jun 15 |
|
Enzyme-assisted synthesis and structure characterization of glucuronide conjugates of methyltestosterone (17 alpha-methylandrost-4-en-17 beta-ol-3-one) and nandrolone (estr-4-en-17 beta-ol-3-one) metabolites. | 2002 Mar-Apr |
|
Successful DNA typing of a urine sample in a doping control case using human mitochondrial DNA analysis. | 2002 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/nandrolone.html
50 to 100 mg per week (women)
100 to 200 mg per week (men)
For children from 2 to 13 years of age, the average dose is 25 to 50 mg every 3 to 4 weeks.
Route of Administration:
Intramuscular
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA14AB01
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
LIVERTOX |
667
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
NDF-RT |
N0000175824
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
NCI_THESAURUS |
C243
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
DEA NO. |
4000
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
WHO-ATC |
A14AB01
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
FDA ORPHAN DRUG |
712219
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
WHO-ATC |
S01XA11
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
WHO-VATC |
QS01XA11
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6PG9VR430D
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
D009277
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
1879
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
3368
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
NANDROLONE
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
7244
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | RxNorm | ||
|
DB00984
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
434-22-0
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
207-101-0
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
C29279
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
6949
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
1454008
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | USP-RS | ||
|
9904
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
295
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
434-22-0
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
M7720
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | Merck Index | ||
|
CHEMBL2104906
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
SUB09148MIG
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE LESS ACTIVE (PARENT)